Skip to main content
Download PDF

Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Trials volume 23, Article number: 999 (2022) Cite this article

The Original Article was published on 08 May 2014

Correction: Trials 15, 160 (2014)

https://doi.org/10.1186/1745-6215-15-160

Following publication of the original article [1], an error was identified between the primary outcome specified in the original protocol, the detailed SAP, and the endpoint forms and a later version of the protocol that this paper was based upon.

The following paragraph in the “Outcomes” section should be changed as follows:

Outcomes

Primary endpoint

Time from randomisation until the first occurring of death or hospitalisation for heart disease (coronary heart disease, arrhythmia, atrial fibrillation, sudden death, resuscitated sudden death), stroke, transient ischaemic attack, peripheral arterial disease or heart failure or first onset of any condition listed above not present at baseline. Primary endpoints will be adjudicated by an independent endpoints committee blinded to treatment arm.

Existing Text:

Outcomes

Primary endpoint

Time from randomisation until the first occurring death, first onset, or hospitalisation for heart disease (coronary heart disease, arrhythmia, new onset/first recorded atrial fibrillation, sudden death, failed sudden death), stroke, or heart failure. Primary endpoints will be adjudicated by an independent Endpoint Committee blinded to the treatment arm.

Reference

  1. Hill NR, Lasserson D, Thompson B, et al. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials. 2014;15:160. https://doi.org/10.1186/1745-6215-15-160.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK

    Nathan R. Hill, Daniel Lasserson, Ben Thompson, Rafael Perera-Salazar, Richard McManus & F. D. Richard Hobbs

  2. NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headley Way, Oxford, OX3 9DU, UK

    Nathan R. Hill, Daniel Lasserson & F. D. Richard Hobbs

  3. Department of Public Health, University of Oxford, Old Road Campus, Headington, Oxford, OX3 7LF, UK

    Jane Wolstenholme

  4. Centre for Primary Care, Institute of Population Health, University of Manchester, Williamson Building, Oxford Road, Manchester, M13 9PL, UK

    Peter Bower & Thomas Blakeman

  5. Primary Care Clinical Sciences, School of Health and Population Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK

    David Fitzmaurice

  6. Primary Medical Care, University of Southampton, Aldermoor Health Centre, Aldermoor Close, Southampton, SO16 5ST, UK

    Paul Little

  7. School of Social and Community Medicine, University of Bristol, Office Room 1.01c, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK

    Gene Feder

  8. School of Medicine, Room 1307 Tower Building, University Park, Nottingham, NG7 2RD, UK

    Nadeem Qureshi

  9. Department of Renal Medicine, Royal Derby Hospital, Uttoxeter Road, Derby, Derbyshire, DE22 3NE, UK

    Maarten Taal

  10. Cardio-Renal Research Group, Departments of Cardiology and Nephrology, Queen Elizabeth Hospital Birmingham and University of Birmingham, Edgbaston, Birmingham, B15 2TH, UK

    Jonathan Townend & Charles Ferro

Authors
  1. Nathan R. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Lasserson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ben Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rafael Perera-Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jane Wolstenholme
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Bower
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Thomas Blakeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Fitzmaurice
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paul Little
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gene Feder
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Nadeem Qureshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Maarten Taal
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jonathan Townend
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Charles Ferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Richard McManus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. D. Richard Hobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. D. Richard Hobbs.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hill, N.R., Lasserson, D., Thompson, B. et al. Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. Trials 23, 999 (2022). https://doi.org/10.1186/s13063-022-06972-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13063-022-06972-9

Trials

ISSN: 1745-6215